Novartis India Limited (NOVARTIND.BO)
INR 789.4
(0.41%)
INR 789.4
(0.41%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 1.26 Billion INR | -45.92% |
| 2022 | 1.23 Billion INR | 120.85% |
| 2021 | 106.6 Million INR | -1.35% |
| 2020 | 598.8 Million INR | 14.21% |
| 2019 | 481.7 Million INR | -18.86% |
| 2018 | 905.4 Million INR | -58.97% |
| 2017 | 1.6 Billion INR | 51.81% |
| 2016 | 953.2 Million INR | -16.79% |
| 2015 | 1.16 Billion INR | 628.03% |
| 2014 | 158.4 Million INR | -78.29% |
| 2013 | 951.39 Million INR | -21.31% |
| 2012 | 976.6 Million INR | -37.23% |
| 2011 | 1.47 Billion INR | -33.26% |
| 2010 | 2.21 Billion INR | 22.16% |
| 2009 | 1.81 Billion INR | 8.52% |
| 2008 | 1.66 Billion INR | 12.79% |
| 2007 | 1.48 Billion INR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 234.65 Million INR | 58.95% |
| 2024 Q2 | 282.7 Million INR | -17.77% |
| 2023 Q4 | 112.1 Million INR | -73.25% |
| 2023 FY | - INR | -45.92% |
| 2023 Q2 | 337.9 Million INR | 13.43% |
| 2023 Q3 | 419 Million INR | 24.0% |
| 2023 Q1 | 297.9 Million INR | 28.57% |
| 2022 Q2 | 233.3 Million INR | -60.1% |
| 2022 Q3 | 161.7 Million INR | -30.69% |
| 2022 FY | - INR | 120.85% |
| 2022 Q4 | 231.7 Million INR | 43.29% |
| 2022 Q1 | 584.7 Million INR | 296.8% |
| 2021 Q4 | -297.1 Million INR | -335.79% |
| 2021 FY | - INR | -1.35% |
| 2021 Q1 | 143 Million INR | -48.08% |
| 2021 Q2 | 134.7 Million INR | -5.8% |
| 2021 Q3 | 126 Million INR | -6.46% |
| 2020 FY | - INR | 14.21% |
| 2020 Q3 | 53.8 Million INR | -65.97% |
| 2020 Q1 | 111.5 Million INR | -41.16% |
| 2020 Q4 | 275.4 Million INR | 411.9% |
| 2020 Q2 | 158.1 Million INR | 41.79% |
| 2019 Q1 | 56.9 Million INR | -82.91% |
| 2019 Q4 | 189.5 Million INR | 16.19% |
| 2019 FY | - INR | -18.86% |
| 2019 Q2 | 72.2 Million INR | 26.89% |
| 2019 Q3 | 163.1 Million INR | 125.9% |
| 2018 FY | - INR | -58.97% |
| 2018 Q4 | 332.9 Million INR | 33.32% |
| 2018 Q3 | 249.7 Million INR | 84.96% |
| 2018 Q2 | 135 Million INR | -28.12% |
| 2018 Q1 | 187.8 Million INR | -78.59% |
| 2017 Q1 | 105.8 Million INR | 19.01% |
| 2017 FY | - INR | 51.81% |
| 2017 Q3 | 262.7 Million INR | -35.97% |
| 2017 Q2 | 410.3 Million INR | 287.81% |
| 2017 Q4 | 877 Million INR | 233.84% |
| 2016 Q1 | 305 Million INR | 198.9% |
| 2016 Q2 | 346.1 Million INR | 13.48% |
| 2016 FY | - INR | -16.79% |
| 2016 Q4 | 88.9 Million INR | -59.68% |
| 2016 Q3 | 220.5 Million INR | -36.29% |
| 2015 FY | - INR | 628.03% |
| 2015 Q4 | -308.4 Million INR | -138.6% |
| 2015 Q3 | 798.9 Million INR | -43.19% |
| 2015 Q2 | 1.4 Billion INR | 560.5% |
| 2015 Q1 | 212.9 Million INR | -54.01% |
| 2014 FY | - INR | -78.29% |
| 2014 Q1 | 217.3 Million INR | 139.71% |
| 2014 Q2 | 223.6 Million INR | 2.9% |
| 2014 Q3 | 54.9 Million INR | -75.45% |
| 2014 Q4 | 462.9 Million INR | 743.17% |
| 2013 Q4 | -547.2 Million INR | -342.45% |
| 2013 FY | - INR | -21.31% |
| 2013 Q3 | 225.7 Million INR | 51.99% |
| 2013 Q2 | 148.5 Million INR | -36.05% |
| 2013 Q1 | 232.2 Million INR | 146.36% |
| 2012 Q4 | -500.9 Million INR | -215.95% |
| 2012 FY | - INR | -37.23% |
| 2012 Q1 | -19.4 Million INR | -103.99% |
| 2012 Q2 | 591.6 Million INR | 3149.48% |
| 2012 Q3 | 432 Million INR | -26.98% |
| 2011 FY | - INR | -33.26% |
| 2011 Q2 | 659 Million INR | 0.0% |
| 2011 Q3 | 568.8 Million INR | -13.69% |
| 2011 Q4 | 486.8 Million INR | -14.42% |
| 2010 FY | - INR | 22.16% |
| 2009 FY | - INR | 8.52% |
| 2008 FY | - INR | 12.79% |
| 2007 FY | - INR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 9.61 Billion INR | 86.801% |
| Aurobindo Pharma Limited | 61.78 Billion INR | 97.946% |
| Glenmark Life Sciences Limited | 6.86 Billion INR | 81.505% |
| Granules India Limited | 8.6 Billion INR | 85.247% |
| Indoco Remedies Limited | 2.64 Billion INR | 52.049% |
| Achyut Healthcare Limited | 524 Thousand INR | -242132.824% |
| Ajanta Pharma Limited | 12.56 Billion INR | 89.898% |
| Alkem Laboratories Limited | 24.19 Billion INR | 94.754% |
| Alpa Laboratories Limited | 86.12 Million INR | -1373.754% |
| Brooks Laboratories Limited | 41.72 Million INR | -2941.842% |
| AstraZeneca Pharma India Limited | 2.35 Billion INR | 46.143% |
| Bajaj HealthCare Limited | 444.51 Million INR | -185.547% |
| Bliss GVS Pharma Limited | 1.47 Billion INR | 14.18% |
| Dr. Reddy's Laboratories Limited | 88.27 Billion INR | 98.562% |
| Eris Lifesciences Limited | 6.98 Billion INR | 81.832% |
| FDC Limited | 4.4 Billion INR | 71.163% |
| Glenmark Pharmaceuticals Limited | 11.34 Billion INR | 88.811% |
| Gufic Biosciences Limited | 1.48 Billion INR | 14.265% |
| Ind-Swift Laboratories Limited | 6.86 Billion INR | 81.501% |
| Ipca Laboratories Limited | 13.29 Billion INR | 90.456% |
| Jagsonpal Pharmaceuticals Limited | 323.46 Million INR | -292.413% |
| Krebs Biochemicals & Industries Limited | -82.72 Million INR | 1634.324% |
| Lasa Supergenerics Limited | -65.08 Million INR | 2050.369% |
| Laurus Labs Limited | 8 Billion INR | 84.146% |
| Lupin Limited | 36.96 Billion INR | 96.567% |
| Mankind Pharma Limited | 28.09 Billion INR | 95.482% |
| Medicamen Biotech Limited | 245.66 Million INR | -416.69% |
| Medico Remedies Limited | 150.37 Million INR | -744.073% |
| Megasoft Limited | 284.73 Million INR | -345.789% |
| NATCO Pharma Limited | 18.79 Billion INR | 93.247% |
| Piramal Pharma Limited | 13.05 Billion INR | 90.278% |
| RPG Life Sciences Limited | 1.28 Billion INR | 0.952% |
| Sigachi Industries Limited | 883.39 Million INR | -43.684% |
| Sun Pharmaceutical Industries Limited | 138.36 Billion INR | 99.083% |
| Suven Pharmaceuticals Limited | 4.67 Billion INR | 72.862% |
| Syncom Formulations (India) Limited | 430.27 Million INR | -194.997% |
| Unichem Laboratories Limited | 742.35 Million INR | -70.983% |
| Wanbury Limited | 985.49 Million INR | -28.799% |
| Windlas Biotech Limited | 781.72 Million INR | -62.373% |
| ZIM Laboratories Limited | 462.09 Million INR | -174.683% |
| Zydus Lifesciences Limited | 56.22 Billion INR | 97.742% |
| Sun Pharma Advanced Research Company Limited | -3.73 Billion INR | 134.018% |
| Divi's Laboratories Limited | 25.43 Billion INR | 95.009% |
| Hester Biosciences Limited | 539.47 Million INR | -135.286% |
| Procter & Gamble Health Limited | 3.01 Billion INR | 57.892% |
| Amrutanjan Health Care Limited | 682.53 Million INR | -85.968% |
| Bal Pharma Limited | 345.59 Million INR | -267.283% |
| Strides Pharma Science Limited | 3.76 Billion INR | 66.284% |
| Venus Remedies Limited | 711.8 Million INR | -78.322% |
| Aarti Pharmalabs Limited | 3.9 Billion INR | 67.532% |
| Nectar Lifesciences Limited | 1.56 Billion INR | 18.832% |
| Shilpa Medicare Limited | 2.58 Billion INR | 50.954% |
| Aarti Drugs Limited | 3.24 Billion INR | 60.928% |
| IOL Chemicals and Pharmaceuticals Limited | 2.6 Billion INR | 51.304% |
| Suven Life Sciences Limited | -992.78 Million INR | 227.853% |
| Ind-Swift Limited | 1.06 Billion INR | -19.176% |
| Valiant Laboratories Limited | 12.73 Million INR | -9863.89% |
| J. B. Chemicals & Pharmaceuticals Limited | 9.33 Billion INR | 86.403% |
| Solara Active Pharma Sciences Limited | -2.82 Billion INR | 144.98% |
| Themis Medicare Limited | 562.6 Million INR | -125.61% |
| Hikal Limited | 2.69 Billion INR | 52.853% |
| Torrent Pharmaceuticals Limited | 35 Billion INR | 96.374% |
| Sequent Scientific Limited | 549.8 Million INR | -130.866% |
| Wockhardt Limited | 1.08 Billion INR | -17.528% |
| Jubilant Pharmova Limited | 8 Billion INR | 84.146% |
| Biofil Chemicals and Pharmaceuticals Limited | 13.06 Million INR | -9617.501% |
| Neuland Laboratories Limited | 4.74 Billion INR | 73.268% |
| Morepen Laboratories Limited | 1.72 Billion INR | 26.458% |
| Kilitch Drugs (India) Limited | 287.42 Million INR | -341.611% |
| Mangalam Drugs & Organics Limited | 174.94 Million INR | -625.538% |